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CME ARTICLE
Cutaneous Lymphomas: An Update. Part 2: B-Cell
Lymphomas and Related Conditions
Werner Kempf, MD,*† Dmitry V. Kazakov, MD, PhD,‡ and Christina Mitteldorf, MD§
Abstract: Primary cutaneous B-cell lymphomas (PCBCL) are the
second most common form of primary cutaneous lymphomas and
account for approximately 25%–30% of all primary cutaneous lympho-
mas. Both forms of low-grade malignant PCBCL, primary cutaneous
follicle center lymphoma (PCFCL) and primary cutaneous marginal zone
lymphoma of mucosa-associated lymphoid tissue-type (MALT lym-
phoma) (PCMZL) represent the vast majority of PCBCL and show an
indolent slowly progressive course and an excellent prognosis despite
a high recurrence rate. Genetic analysis indicates that PCMZL differ from
other forms of extranodal MALT lymphomas. The more common class-
switched and the non–class-switched form of PCMZL can be distin-
guished as two distinctive subsets that differ in the cellular composition,
IgM expression, and biological behavior with extracutaneous involve-
ment found in the non–class-switched form. Recently, unusual clinical
and histological forms of PCMZL and PCFCL manifesting with miliary
or agminated lesions have been described that are diagnostically chal-
lenging. In contrast to PCMZL and PCFCL, primary cutaneous diffuse
large B-cell lymphoma, leg type, and other rare forms of large B-cell
lymphomas such as intravascular large B-cell lymphoma have an unfa-
vorable prognosis. There is an emerging group of Epstein–Barr virus
(EBV)–driven B-cell lymphoproliferations including posttransplant
lymphoproliferative disorders and mucocutaneous ulcer occurring in
immunocompromised patients and EBV-associated diffuse large B-cell
lymphoma of the elderly arising in the setting of senescence-linked
immunodeﬁciency. This review reports on recent ﬁndings expanding
the spectrum of clinicopathological features, differential diagnostic as-
pects, and the pathogenesis of PCBCL and discusses the group of
EBV-associated B-cell lymphoproliferations involving the skin.
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LEARNING OBJECTIVES
After participating in this activity, physicians should
be better able to:
1. Identify the characteristics of primary cutaneous B-cell
lymphomas (PCBCL).
2. Evaluate the relationship between PCBCL and Epstein-
Barr virus.
3. Choose the appropriate differential diagnosis.
CUTANEOUS B-CELL LYMPHOMAS
Primary cutaneous B-cell lymphomas (PCBCL) are the
second most common form of primary cutaneous lymphomas
(PCL) and account for approximately 25%–30% of all PCL.1
Both forms of low-grade malignant PCBCL, primary cutaneous
follicle center lymphoma (PCFCL) and primary cutaneous mar-
ginal zone lymphoma (PCMZL) [extranodal mucosa-associated
lymphoid tissue (MALT)-type lymphoma], represent the vast
majority of PCBCL and show an indolent slowly progressive
course and an excellent prognosis despite a high recurrence
rate. In contrast, primary cutaneous diffuse large B-cell lym-
phoma, leg type (PCDLBCL-LT) and other rare forms of large
B-cell lymphomas have an impaired prognosis.
The current World Health Organization (WHO) classi-
ﬁcation (fourth edition, 2008) integrates the achievements of
the WHO-European Organization for Research and Treatment
of Cancer (EORTC) classiﬁcation (2005) by pursuing its
diagnostic criteria for PCBCL (Table 1). Particularly, PCFCL
and PCDLBCL-LT are clearly deﬁned and thus can be repro-
ducibly distinguished by their histology and phenotype.1–4 By
deﬁnition, PCBCL are limited to the skin at the time of diag-
nosis. The indolent forms often remain conﬁned to the skin
during their course. In comparison to cutaneous T-cell lym-
phomas, PCBCL display a more uniform clinical presentation
and manifest in most cases with nodules, but plaque-like
lesions and papules may be observed. The distribution of
the lesions differs between the PCBCL entities, with PCFCL
affecting predominantly the head and neck area, whereas
PCMZL is typically found on the trunk and arms. The lower
extremities, particularly the lower legs, are the predilection
site of PCDLBCL-LT. Thus, clinico–pathologic correlation
provides important information for the diagnosis. Differenti-
ation of PCMZL and PCFCL from B-cell pseudolymphoma
(B-PSL) (synonymously lymphocytoma cutis) is challenging
due to a signiﬁcant overlap of clinical, histological, and phe-
notypic features. The detection of monotypic plasma cells
and/or monoclonal rearrangement of immunoglobulin (Ig)
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heavy chain genes (IgH) are considered to be useful adjunc-
tive diagnostic elements for the diagnosis of PCBCL. The
BIOMED-2 protocol represents an internationally elaborated
and accepted method for the polymerase chain reaction
(PCR)–based analysis of Ig heavy chain genes.5 It has to be
emphasized that the molecular data have to be interpreted in
the context of clinical, histological, and phenotypic ﬁndings.
Additional examinations include search for serum antibodies
against Borrelia species or PCR-based identiﬁcation of bor-
relia DNA in cases of PCMZL and Epstein–Barr virus (EBV)
by in situ hybridization (EBER), particularly in B-cell inﬁl-
trates with centroblastic, immunoblastic, and plasmacytic or
plasmablastic differentiation. Staging examinations are essen-
tial to exclude secondary cutaneous involvement by nodal or
other extranodal B-cell non-Hodgkin lymphomas, with which
PCBCL share morphological and immunophenotypic fea-
tures. Apart from history, hematological and serological tests,
staging examinations include radiologic examinations (CT or
PET-CT) and bone marrow biopsy. The necessity of bone
marrow biopsy in the staging of PCMZL and PCFCL is
controversially discussed. The latter should be performed in
the workup of high-grade malignant PCBCL such as
PCDLBCL-LT or intravascular lymphoma but regarded as
optional in low-grade malignant CBCL such as PCFCL and
PCMZL according to the International Society for Cutaneous
Lymphomas European Organization for Research and Treat-
ment of Cancer (ISCL-EORTC) guidelines.6 The TNM sys-
tem proposed by the ISCL-EORTC has been proven to be
useful tool to document disease extent in patients with
PCBCL and provides prognostic information.7,8 This review
reports on recent ﬁndings on clinicopathological features and
pathogenetic aspects of PCBCL and the emerging group of
EBV-associated B-cell lymphoproliferations.
Primary Cutaneous Marginal
Zone Lymphoma
PCMZL is deﬁned as an indolent B-cell lymphoma
composed of small B cells, marginal zone cells, lymphoplasma-
cytoid cells and mature plasma cells.1,9 In the WHO classiﬁca-
tion (fourth edition, 2008), PCMZL belongs to the group of
extranodal marginal zone lymphoma of MALT lymphoma.4,10
Recent data, however, indicate that most cases of PCMZL differ
from other forms of extranodal MALT lymphoma with regard to
the expression of class-switched immunoglobulins, chemokine
receptors, translocations, and associated infectious agents.11,12
PCMZL manifests in most patients with multifocal
nodular lesions, most commonly located on the trunk and
arms.3,13 The nodules are usually less than 3 cm in diameter.
Rare clinical variants include an anetodermic form and an
agminated form of PCMZL the latter simulating granuloma-
tous rosacea, which both may clinically be misinterpreted as
inﬂammatory diseases.14–16 The anetodermic form of PCMZL
is associated with antiphospholipid antibodies indicating
immunologic disorders in a subset of patients.
PCMZL is histologically characterized by conﬂuent
nodular lymphocytic inﬁltrates, which are centered in the
dermis and may extend into the subcutis (Fig. 1). The inﬁl-
trates are composed of small lymphocytes, lymphoplasma-
cytoid cells, mature plasma cells, and reactive germinal
centers with tingible body macrophages9,17 (Fig. 2). Marked
plasmacytic differentiation and/or a prominent T-cell com-
ponent may obscure the neoplastic B cells in PCMZL.18 A
subset of PCMZL is characterized by a predominance of
monocytoid B cells instead of lymphoplasmacytic cells.
Tumor cells express CD20 and bcl-2 but are negative for
bcl-6 (Fig. 3).
FIGURE 1. PCMZL (extranodal MALT lymphoma): dermal
nodular infiltrates of small lymphocytes, magnification ·10.
TABLE 1. Cutaneous B-Cell Lymphomas According to the
WHO Classification for Haematopoietic and
Lymphoproliferative Disorders (Fourth Edition, 2008) and the
WHO-EORTC Classification
WHO-EORTC
Classiﬁcation (2005)
WHO Classiﬁcation
(Fourth Edition, 2008)
Primary cutaneous marginal
zone B-cell lymphoma
Extranodal marginal zone lymphoma of
mucosa-associated lymphoid tissue
(MALT lymphoma)
Primary cutaneous follicle
center lymphoma
Primary cutaneous follicle center
lymphoma
Growth patterns: follicular
Follicular and diffuse
Diffuse
Diffuse large B-cell lymphoma, NOS:
Primary cutaneous diffuse large
B-cell lymphoma, leg type
Primary cutaneous diffuse large B-cell
lymphoma, leg type
Primary cutaneous diffuse large
B-cell lymphoma, other
EBV-positive diffuse large B-cell
lymphoma of the elderly
Primary cutaneous intravascular
large B-cell lymphoma
Intravascular large B-cell lymphoma
Plasmablastic lymphoma
Post-transplant lymphoproliferative
disorders (PTLD)
WHO, World Health Organization; WHO-EORTC, World Health Organization-
European Organization for Research and Treatment of Cancer.
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Two distinctive subsets of PCMZL have recently been
delineated12: (1) the more common class-switched form of
PCMZL with perivascular and periadnexal nodular inﬁltrates
containing plasma cells expressing IgG, IgA, or IgE and
numerous T cells in the vast majority of the cases. The reac-
tive follicles express IgD and B cells lack CXCR3. Extrac-
utaneous involvement was not found in the class-switched
PCMZL. (2) The rare non–class-switched form of PCMZL
histologically presents itself with large nodules of B cells,
which express CXCR-3 in half of the cases and show a lower
number of admixed T cells. The reactive follicles are IgM
positive. Remarkably, in the series reported by Edinger
et al, extracutaneous involvement was observed in 3 of 6
cases of the non–class-switched form of MZL.
Due to a signiﬁcant overlap in clinicopathological
features, differentiation of PCMZL from B-PSL is difﬁcult
and may be impossible in individual cases. Multifocal
presentation, demonstration of monoclonality, and relapsing
course are in favor of PCMZL. The observation of multifocal
or even miliarial type of B-PSL somehow limits the value of
multiple lesions as an argument in favor of PCMZL.19 Mono-
typic plasma cells are considered as a major diagnostic crite-
rion for PCMZL, but there is no consensus on the ratio of Ig
light chains required for monoclonality. A ratio of 5:1 to 10:1
is considered by most experts as monoclonal. So-called pseu-
doclonality due to the presence of different B-cell clones, that
is, oligoclonal B-cell inﬁltrates, is a pitfall in the assessment
of clonality by PCR and is more commonly found in cases
with sparse B-cell inﬁltrates.20 Thus, only the demonstration
of the same clone in repeated assays proves monoclonality.
Cutaneous involvement by B-cell chronic lymphocytic
leukemia (B-CLL) may sometimes simulate PCMZL, but
differences in immunophenotype are substantial to distinguish
between the 2 disorders. Tumor cells in B-CLL express CD5,
CD23, and CD43, whereas PCMZL do not show expression
of CD5 and CD43.21,22 Another potential diagnostic pitfall is
secondary cutaneous involvement of other extranodal MALT
lymphoma that is histologically and phenotypically similar if
not identical with PCMZL. Clinically, PCMZL is more com-
monly seen in younger patients and favors the trunk and
extremities as predilection sites, whereas MZL secondarily
involving the skin affects more commonly older patients
and involves more often the head/neck regions.23
In the WHO-EORTC and the current WHO classiﬁca-
tions, the former lymphoma entities, cutaneous immunocytoma
and primary cutaneous plasmacytoma, are considered to
represent variants of PCMZL.1,9 Clinically, cutaneous immuno-
cytoma manifests with nodules, which have a smooth surface
and may be located on top of acrodermatitis chronica atrophi-
cans. The dense dermal inﬁltrates are almost exclusively com-
posed of plasma cells with monotypic expression of Ig light
chains. Differential diagnosis includes secondary cutaneous
inﬁltrates by extramedullary plasmacytoma. Furthermore, veg-
etating herpes simplex virus infection in HIV patients may
present with ulcerated tumor-like lesions, but they are composed
predominantly of mature plasma cells with polytypic Ig light
chain expression. The diagnostic epithelial changes pathognom-
ic for alpha-herpesvirus infection may be very subtle and only
seen on serial sections.
It remains a matter of debate whether PCMZL repre-
sents a de novo neoplastic process or whether B-cell PSL and
PCMZL represent different evolutionary steps of a lympho-
proliferative reaction to various exogenous and/or endoge-
nous antigens. The association with borrelia infection, the
observation of spontaneous involution, and a similar cellular
composition of the inﬁltrate in both B-cell PSL and PCMZL
are in favor of the latter concept. The expansion of differing
clones in multiple lesions of PCMZL may be due to variable
immune response to a chronic antigenic stimulus.24 Transient
proliferations of postgerminal center cells, which are referred
to as marginal zone hyperplasia in tonsil and appendix, could
FIGURE 2. PCMZL (extranodal MALT lymphoma): tumor cells
with lymphoplasmacytic differentiation and mature plasma
cells, magnification ·100.
FIGURE 3. PCMZL (extranodal MALT lymphoma): expression
of bcl-2 by tumor cells. Reactive germinal centers are spared,
magnification ·25.
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represent an transitional or intermediate step also in the skin,
but its relationship to PCMZL remains to be elucidated. At
present, the concept of marginal zone hyperplasia in mucosa
or skin is limited to lambda light chain restriction and to the
observation only in the pediatric population.25 Detection of
plasmacytoid dendritic cells (PDC) arranged in clusters in all
cases of PCMZL and in most B-cell PSL suggests common
pathogenetic pathways26 (Fig. 4). We hypothesized that PDC
in both processes activate CD4+ T cells and promote survival
of antigen-activated T cells which themselves stimulate
growth of B cells.27 The chronically stimulated B cells can
undergo somatic hypermutation and additional other genetic
alterations, which ﬁnally render the process independent of
the initial antigenic stimulus as it also has been shown in
gastric MALT lymphoma.10,28 However, in other studies,
clusters of PDC were not detected in all cases. For example,
Edinger et al12 identiﬁed clusters of PDC only in 1 of the 8
cases studied and in another case, the cells were dispersed,
whereas no PDC were noted in the remaining 6 cases.
In a subset of PCMZL cases, Borrelia species and hep-
atitis C virus sequences could be found, but they may be only
2 of several infectious agents linked to PCMZL.29,30 Never-
theless, even in Europe, PCMZL is only rarely associated
with Borrelia species31
PCMZL has an excellent prognosis with a 5-year
survival rate of more than 95%.3,13 Recurrences are common
and occur in up to 50% of the patients but are not linked to an
impaired prognosis. Extracutaneous spread is seen in less than
10% of the patient but may be more commonly seen in the
non–class-switched subtype of the disease as discussed
above.12 Systemic involvement in PCMZL may be preceded
by large cell transformation, which is a rare event in
PCMZL.32 The presence of both the t(14; 18)(q32; q21)
IGH/BCL2 and the t(14; 18)(q32; q21) IGH/MALT1 trans-
locations in PCMZL was seen in cases of PCMZL with trans-
formation toward higher-grade B-cell lymphoma.33
Primary Cutaneous Follicle Center Lymphoma
Primary cutaneous follicle center lymphoma (PCFCL)
represents a tumor of neoplastic follicle center cells and is
predominantly composed of centrocyte-like tumor cells with
cleaved nuclei.1 In the current WHO classiﬁcation (fourth
edition, 2008), PCFCL is listed as a separate entity and not
only as a variant of extranodal follicular lymphomas.4 PCFCL
affects patients in their ﬁfth to seventh decade with a median
age of onset of approximately 50 years and a male to female
ratio of 1.5:1. The predilection site is the head and neck area
and upper trunk. Erythematous plaques or nodules of ﬁrm
consistency and a smooth surface represent the most common
clinical presentation. In almost 90% of the patients, the dis-
ease presents at diagnosis in tumor stage T1 (solitary lesion)
or T2 (regional tumoral lesions).3 PCFCL slowly enlarges and
may grow to tumors of large size (up to several centimeters).
In some patients, those large tumors may even destroy under-
lying anatomical structures such as bone.34 Large tumors of
PCFCL on the back have originally been referred to as retic-
ulohistiocytoma dorsi (Crosti’s lymphoma). Miliary and ag-
minated type of PCFCL represent a unique and diagnostically
misleading clinical presentation of the disease. In a series of
18 patients, all patients presented with multiple, erythematous
ﬁrm papules arranged in a manner that resembled millet seeds
or collected together in small clusters predominantly on the
head and neck.35 Lymphoma was not suspected at initial
diagnosis in any of the patients but was conﬁrmed by histol-
ogy. An anetodermic form has also been observed in PCFCL
as a rare variant, in which some of the tumoral lesions regress
leaving behind anetoderma.15
Histologically, 3 growth patterns can be discerned:
a follicular, a follicular and diffuse (mixed), and a diffuse
pattern. The follicular pattern is characterized by large
neoplastic follicles and is mostly composed of centrocyte-
like cells (Figs. 5, 6). In contrast to the reactive germinal
centers in B-cell PSL and PCMZL, the neoplastic follicles
in PCFCL are devoid of tingible body macrophages in 90%
of the cases.36 The diffuse growth pattern in PCFCL does not
represent the consequence of tumor progression from follic-
ular to diffuse pattern. A recent study showed that already the
early lesions in diffuse pattern of PCFCL consist mostly of
FIGURE 4. PCMZL (extranodal MALT lymphoma): clusters of
CD123-positive plasmacytoid dendritic cells in the periphery
of the infiltrates. Immunohistochemistry, magnification ·100.
FIGURE 5. Primary cutaneous follicle center lymphoma:
nodular infiltrate with large neoplastic follicular structures,
magnification ·20.
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solitary or clustered papules and small nodules located on the
trunk and presented with the characteristic histological fea-
tures, that is, aggregates of medium and large centrocytes
admixed with small lymphocytes without the formation of
follicular structures.37 The tumor cells in PCFCL express B-
cell markers (CD20, Pax5) and bcl-6 in all cases. Expression
of bcl-2, which is a characteristic feature of nodal follicular
lymphoma, is found in only a minority (approximately 10%–
20%) of PCFCL.38 In PCFCL, the presence or absence of bcl-
2 expression and/or t(14; 18) translocation is not linked to
differences in clinical presentation or prognosis.1 The expres-
sion of bcl-2 should always raise the suspicion for secondary
cutaneous inﬁltrates of a nodal follicular lymphoma. Prolifer-
ating cells (Ki-67+ or MIB-1+) are scattered throughout the
entire inﬁltrate, which contrasts the high proliferative activity
centered in the reactive germinal centers in B-PSL. Large
irregular networks of CD21-positive follicular dendritic cells
(FDC) are seen in the follicular form. Remnants of these
networks are also discernible in PCFCL with diffuse growth
pattern, whereas primary cutaneous diffuse large B-cell lym-
phoma, leg type (PCDLBCL-LT) lacks networks of FDC.
Monoclonal rearrangement of IgH genes can be detected in
up to 90% of the cases using BIOMED-2 primers.39 Second-
ary cutaneous involvement by mantle cell lymphoma, which
accounts for approximately 10% of nodal B-cell Non-Hodgkin
lymphoma, has to be considered in the differential diagnosis.
It presents with disseminated macules, papules, plaques, or
nodules.40 The diffuse inﬁltrates are composed of blasts or
centrocyte-like tumor cells and therefore may mimic PCFCL41
(Fig. 7). Phenotypic analysis is very useful, because the tumor
cells in mantle cell lymphoma express CD5 and cyclin D1,
which are both negative in PCFCL and PCMZL. In addition,
the tumor cells in mantle cell lymphoma are negative for CD23
in contrast to B-CLL.
Importantly, some B-PSL located at certain anatomic
sites such as the nipple and scrotum often show features
accounting for a signiﬁcant overlap with PCFCL.42,43 In
those cases, coalescing lymphoid follicles with nonpolarized
germinal centers lacking mantle zones and smudged inﬁl-
trates of lymphoid cells spreading into collagen (often as
single-cell ﬁles), smooth muscle, vessel walls, and periph-
eral nerve sheaths may result in diagnostic challenge and
mimic PCFCL.
Although recurrences are seen in up to 40% of the
patients with PCFCL, this form of PCBCL has an excellent
prognosis with a 5-year survival rate of more than 90%.1,3
Extracutaneous spread occurs rarely, that is, in approximately
10% of the patients. PCFCL arising at the legs and those
cases with expression of FOX-P1 seem to have a worse prog-
nosis and should be treated more aggressively similar to
DLBCL-LT.6 CBCL with spindle cell morphology, some of
them belonging to PCFCL, others to PCDLBCL, may require
higher attention for extracutaneous spread.44
Primary Cutaneous Diffuse Large
B-Cell Lymphoma
Primary cutaneous diffuse large B-cell lymphoma
(DLBCL) is characterized by dense nodular or diffuse
inﬁltrates predominated by centroblast-like and immuno-
blast-like tumor cells with noncleaved, that is, round nuclei.
The DLBCL-LT represents the most common type of
DLBCL and is listed as a distinct subtype of DLBCL in the
current WHO classiﬁcation (fourth edition, 2008). In 80% of
the patients, DLBCL-LT manifests with solitary or multiple
rapidly growing nodules located on the legs, particularly on
the lower legs (Fig. 8). DLBCL-LT affects elderly patients in
their seventh and eight decades with a strong female prepon-
derance (male to female ratio, 1: 3–4). Histologically,
DLBCL-LT shows diffuse inﬁltrates of centroblast- and im-
munoblast-like cells with mitotic activity (Figs. 9, 10). There
are only few admixed small lymphocytes or other reactive
cells. Uncommon histological presentations include epidermo-
tropic, angiocentric, anaplastic, and spindle cell variants.45
Phenotypically, tumor cells in DLBCL-LT strongly express
bcl-2 and MUM-1, but in most cases, they show weak expres-
sion of bcl-6 or are negative for bcl-6 and CD1046 (Fig. 11).
FIGURE 6. Primary cutaneous follicle center lymphoma:
centrocyte-like tumor cells with cleaved nuclei, magnification
·250.
FIGURE 7. Mantle cell lymphoma: secondary cutaneous
involvement by tumor cells with centrocyte-like differentia-
tion, magnification ·400.
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IgM expression was identiﬁed as an additional adjunctive
diagnostic marker, which is found in all cases of DLBCL-
LT but only rarely in PCFCL (9%).47 In contrast to PCFCL,
networks of CD21-positive FDC are not found in DLBCL-LT.
In regard to the prognostic and therapeutic implications, the
most relevant differential diagnosis of DLBCL-LT is PCFCL
with diffuse growth pattern that is based on cytomorphology
(centrocyte-like vs. centroblast- and immunoblast-like differ-
entiation) and the phenotype (bcl-2, bcl-6, MUM-1, IgM) (for
review see also ref. 48) (Table 2). MUM-1 is diffusely positive
in DLBCL-LT that is helpful while differentiating the disease
from PCFCL in which neoplastic cells are negative or display
a low expression of MUM-1. FoxP1 is also a useful marker to
this end. A diagnostic pitfall may result from CD30 expression
in large B-cell lymphoma mimicking anaplastic large T-cell
lymphoma, but expression of CD20 and absence of T-cell
markers lead to the diagnosis.49,50
In contrast to low-malignant CBCL such as PFCFL and
PCMZL, DLBCL-LT has a poor prognosis with 5-year
survival rates ranging from 20% to 60%.51 Genetic analysis
revealed chromosomal loss of 9p21, which encodes p16, as
a negative prognostic marker in PCDLCBL-LT.52 Loss of p16
assessed by immunohistochemistry, however, does not corre-
late with these ﬁndings indicating the necessity for genetic
analysis by reverse transcription–PCR or ﬂuorescence in situ
hybridization analysis. Recurrent deletions in 9p21 (p14
(ARF)/p16(INK4a/CDKN2A) have been found to be a con-
stant ﬁnding in DLBCL-LT, whereas PCFCL does not exhibit
this change.53 Factors indicating a poor prognosis in DLBCL-
LT include the presence of multiple tumors, involvement of
both legs, chromosomal loss of 9p21, and activation of
nuclear factor kB pathway with inhibition of antiapoptotic
proteins.51,52,54 DLBCL-LT requires chemotherapy in combi-
nation with rituximab, particularly in patients with multiple
FIGURE 8. PCDLBCL-LT: solitary large tumor on the lower leg. FIGURE 9. PCDLBCL-LT: dense diffuse infiltrates in the entire
dermis, magnification ·20.
FIGURE 10. PCDLBCL-LT: the tumor cells display a centroblast-
like and immunoblast-like differentiation, magnification ·400.
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tumors.6 Solitary lesions may be excised and/or treated by
radiation.
The term primary cutaneous DLBCL, other refers to
cases of large B-cell lymphomas not belonging to DLBCL-
LT.1 Primary cutaneous DLBCL, other, is a very rare and still
poorly characterized form of DLBCL that shares cytological
features with DLBCL-LT, that is, inﬁltrates composed of
centroblast- and immunoblast-like cells but differ in regard
to the phenotype1 with expression of bcl-6 in all cases, MUM-
1 in 67%, and FOX-P1 in 50% of the cases. In sharp contrast
to DLBCL-LT tumor cells in DLBCL, others are negative for
bcl-2 (Table 3). Occasionally, numerous small lymphocytes
in addition to the large centroblast- and immunoblast-like
tumor cells may be present in DLBCL, other (Fig. 12). Fur-
thermore, DLBCL, other includes morphological variants
such as anaplastic or plasmablastic subtypes of DLBCL or
T-cell/histiocyte-rich large B-cell lymphomas.1
Intravascular large B-cell lymphoma is a rare form
of extranodal large B-cell lymphoma. As the designation
implies, intravascular large B-cell lymphoma is characterized
by the intravascular growth of large B cells especially in small
vessels, particularly capillaries and venules.55 A defect in
homing receptors on tumor cells (CD29 = beta1 Integrin;
CD54 = ICAM1) is considered to be responsible for the
unique intravascular growth pattern.56 Any organ can be
involved, although lymph nodes are usually spared. Skin
involvement manifests with livedo-like reticular erythema,
panniculitis, or painful telangiectasias simulating inﬂamma-
tory diseases or with nodules.57 Clinical symptoms include B
symptoms (fever, night sweat, weight loss) in half of the
patients and neurologic deﬁcits. A systemic and a cutaneous
form are distinguished. The cutaneous form displays a better
prognosis with 3-year survival rate of 56% compared with
systemic form (33%).55 In the skin, small dermal and sub-
cutaneous vessels are ﬁlled with large B cells with pleomor-
phic, moderately chromatin dense nuclei and abundant
cytoplasm (Fig. 13). Occasionally, tumor cells colonize he-
mangiomas.58,59The tumor cells express CD20 and bcl-2 and
may be positive for CD5 and/or CD10. A rare T-cell and
natural killer (NK) cell variant of intravascular lymphomas
has been described and is associated in some cases with
EBV.60 Iacobelli et al61 reported on a case of intravascular
anaplastic large cell lymphoma restricted to the skin. The
T-cell and NK-cell variant is not included as a distinct entity
or subtype in the current WHO classiﬁcation. Differential
diagnosis includes intralymphatic histiocytosis as it can be
seen after orthopedic metal implantation.62 Benign intravas-
cular CD30+ T-cell proliferation occurring after trauma or as
a consequence of inﬂammatory skin diseases has to be differ-
entiated from the rare T-cell variant of intravascular
lymphoma.63,64
EBV-Associated B-Cell Lymphoproliferations
EBV is a g-herpesvirus that is pathogenetically linked to
the development of several B-cell, T-cell, and NK-cell lympho-
proliferative disorders. Among the increasing spectrum of
EBV-associated B-cell lymphoproliferations, EBV-positive
DLBCL of the elderly, plasmablastic lymphoma (PBL),
EBV-positive mucocutaneous ulcer, and lymphomatoid granu-
lomatosis (LYG) are of particular dermatopathologic interest.
EBV-positive DLBCL of the elderly is an EBV-positive
B-cell lymphoma that occurs in patients older than 50 years of
age (with a median age of 71 years) and without any known
immunodeﬁciency or previous lymphoma. Nevertheless, the
immunological deterioration or senescence in immunity as part
FIGURE 11. PCDLBCL-LT: the tumor cells show strong expression
of bcl-2, magnification ·250.
TABLE 2. Primary Cutaneous Follicle Center Lymphoma and—Histological and Phenotypic Features
Primary Cutaneous Follicle Center Lymphoma Primary Cutaneous Diffuse Large B-Cell Lymphoma, leg type
Clinical features Nodules and surroundings plaques mostly on the head and
neck or upper trunk
Ulcerated large nodules mostly on the lower legs
Histology Predominantly centrocyte-like cells Predominantly centroblast- and immunoblast-like cells
Phenotype CD20/CD79a/Pax5 CD20/CD79a/Pax5
bcl-6+ bcl-62/+
bcl-22 bcl-2++
MUM-1- MUM-1+
IgM2 IgM+
CD21/CD35: irregular networks or remnants of FDC networks CD21/CD35: lack of FDC networks
Prognosis Favorable: 5-year survival rate: 95% Poor: 5-year survival rate: 20%–60%
FDC, Follicular dendritic cells.
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of the aging process is assumed to play a pathogenetic role in
the development of this lymphoma, which involves most com-
monly extranodal sites (70%), especially skin, lung, tonsil, and
stomach.65
Histologically, diffuse inﬁltrates of immunoblast-like
and/or plasmablast-like cells with intermingled tingible body
macrophages and geographic necroses are seen. The tumor
cells express B-cell markers (CD20, CD79a, Pax-5) and
MUM-1/IRF4 but generally lack expression of CD10 and
bcl-6. CD30 expression and Ig light chain restriction are
variable. The tumor cells show a high proliferation rate.
Association with EBV is best demonstrated by the detection
of EBER using in situ hybridization, but some of the cases
also show expression of latent membrane protein 1 and
EBNA-2.66,67 The disease runs an aggressive course with
a median survival of 2 years.66 EBV-positive DLBCL of
the elderly and PBL share overlapping features.68,69
Plasmablastic lymphoma (PBL) is a rare variant of
DLBCL that almost exclusively develops in the setting of
HIV infection or other immune deﬁciencies including post-
transplant. An etiological role for EBV has been established.
PBL mostly manifests in the oral cavity but also involves the
skin on rare occasion. To date, less than 30 PBL cases present-
ing in the skin have been documented.69–71 Risk factors for the
development of the lymphoma in the setting of organ trans-
plantation include younger age, higher rejection frequency, and
high-dose cyclosporine therapy. Occurrence in apparently
immunocompetent previously healthy patients is exceptional.
The disease is characterized by an aggressive course with mean
survival of 6 months. HIV-infected patients seem to have
a more favorable prognosis compared with patients after trans-
plantation. In addition, more recently, human herpesvirus 8
(HHV-8) has also been implicated in this lymphoma type.72-
Clinically, cutaneous involvement is characterized by solitary
or multiple asymptomatic skin-colored or violaceous nodules
and papules located on the trunk and limbs ranging in size from
0.5 to 12 cm. Large ulcerated tumors on the lower legs clini-
cally simulating DLBCL-LT have been described.69 Histolog-
ically, there is a diffuse or multinodular proliferation composed
of immunoblast-like cells or markedly atypical cells with plas-
macytic differentiation, that is, eccentrical nucleus with
a “clock-faced” chromatin, a discrete perinuclear hof and abun-
dant cytoplasm (Fig. 14). Multinucleated forms (binucleated
and trinucleated forms) can be observed. Some of the tumor
cells manifest a frankly blastic appearance with more centrally
located nuclei and ﬁnely dispersed chromatin. Mitotic ﬁgures
are usually numerous and atypical. Immunohistochemically,
the neoplastic cells express plasma cell markers including
CD38, CD138, and VS38c, whereas they lack expression of
B-cell markers such as CD20 and Pax-5. Variable expression is
seen with CD10, CD79a, CD30, and CD56. EBV has been
TABLE 3. Immunophenotypic Features in Primary Cutaneous Follicle Center Lymphoma, Diffuse Growth Pattern (PCFCL) in
Comparison to PCDLBCL-LT and DLBCL, other. The Percentages of Markers Are Based on the Data Published in the Literature.46,47,90,91
Centrocyte-Like Cells Centroblast- and Immunoblast-Like Cells
Cytomorphology FCL, Diffuse PCDLBCL, Leg Type DLBL, Others
Site Nonleg, 90% Leg, 10% Leg, 80% Nonleg, 20% Leg/Nonleg, 56%/44%
Marker (%)
Bcl-2 7–22 40 93–100 67–70 0
Bcl-6 93 67 57–75 80 100
MUM-1 0–7 57 76–92 41–75 67
FOXP1 10 20 72–80 100 50
CD10 7–18 0 0 0 14
FIGURE 12. Primary cutaneous diffuse large B-cell lymphoma,
other: tumor cells with centroblast-like differentiation inter-
mingled with numerous small lymphocytes, magnification ·200.
FIGURE 13. Intravascular large B-cell lymphoma: large atypical B
cells in the lumen of a small dermal vessel, magnification ·250.
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demonstrated in a majority of cases with EBER transcripts
often found in virtually all tumor cells (Fig. 15).
Posttransplant lymphoproliferative disorder represents
a spectrum of lymphoid diseases, ranging from early lesions,
such as plasmacytic hyperplasia, to monomorphic neoplasms.
Fifty cases of primary cutaneous B-cell posttransplant lympho-
proliferative disorder were recently reviewed.73 They usually
manifest several years after transplantation, show a male pre-
ponderance, tend to occur on extremities, are frequently EBV
associated, and were associated with a favorable clinical out-
come. Histologically, some of these cases show plasmacytoma-
like features.74,75 Similar B-cell lymphoproliferations in patients
with drug-related immunosuppression outside of organ trans-
plantation have been reported.50,76,77 They mostly have a large
cell morphology and may be associated with EBV.
Lymphomatoid Granulomatosis
LYG is a rare B-cell proliferation with primarily
extranodal involvement, affecting the lungs, skin, CNS, and
the kidneys.78 The skin is secondarily involved in 20%–50%
of LYG patients. The cutaneous manifestations may include
papulonodular lesions, subcutaneous inﬁltrations, ulcerations,
and facial edema.79,80 Histologically, angiocentric inﬁltrates
with large atypical B cells are found in a background of
a dense inﬁltrate of reactive T cells, histiocytes, and plasma
cells.81,82 Association with EBV is found in most of the cases
with EBER transcripts present in B cells.
EBV-positive mucocutaneous ulcer is a recently
described B-cell lymphoproliferative disease that manifests
with isolated sharply demarcated ulceration most commonly
in the oropharynx, skin, and gastrointestinal tract.83 A third
of the affected patients has a drug-related immunosuppression,
but age-related immune suppression is also a feature.83,84 Poly-
morphous inﬁltrates of atypical large B-cell blasts, often with
Hodgkin or Reed-Sternberg cell-like morphology in the back-
ground of abundant small T cells and eosinophils, are found.
The large cells express CD20 and CD30 and are positive for
EBER. Spontaneous regression was observed in half of the
patients and occurred on withdrawal of immunosuppressive
drugs. Relapses were rare, and complete remission was seen
in all patients. A case of EBV-positive + mucocutaneous ulcer
with concomitant TCR-g/IgH rearrangements has recently been
reported85 thereby extending the spectrum of lymphoprolifera-
tions with dual genotype.86 EBV-positive mucocutaneous ulcer
has to be distinguished from traumatic ulcerative granuloma
with stromal eosinophilia, which harbors CD30+ T cells in
more than half of the cases (71%) and clonal T cells in 24%
of the cases, and may represent a CD30+ T-cell lymphoprolif-
erations in the oral mucosa.87–89
In summary, PCBCL represent a morphologically and
prognostically heterogenous group of B-cell proliferations.
Clinicopathological correlation, phenotyping, and staging
examinations are essential diagnostic elements in the diag-
nostic workup of PCBCL. Genetic proﬁling allows to identify
subsets with a more aggressive behavior. EBV may be
involved particularly in B-cell proliferations arising in
immunosuppressed patients.
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After completing this CME activity, physicians should be better able to diagnose the cutaneous deposition
disorders, distinguish the clinical, histopathologic and immunohistochemical features of these often-confusing entities,
classify lesions into one of the ﬁve categories of cutaneous deposits, and identify the speciﬁc substance involved in the
cutaneous deposit.
1. Which statement about primary cutaneous marginal zone lymphoma (PCMZL) is correct?
a) Cutaneous inﬁltrate of B-cell chronic lymphocytic leukemia is an important histologic differentialdiagnosis.
b) PCMZL is commonly associated with borrelia infection.
c) PCMZL more commonly affects older patients (.70 years).
d) The lack of monoclonal plasma cells excludes the diagnosis of PCMZL.
2. Which statement about primary cutaneous follicle center cell lymphoma (PCFCL) is correct?
a) The tumor cells in PCFCL express bcl-2 in the majority of the cases.
b) PCFCL arising at the legs have a worse prognosis.
c) The 5-year survival rate of PCFCL is about 60%.
d) Immunohistochemistry is not helpful in differentiating PCFCL from cutaneous inﬁltrates of mantle cell lymphoma.
3. Diffuse large B-cell lymphoma, leg-type (DLBCL-LT):
a) Is typically positive for bcl-2 and MUM-1.
b) Lacks expression of cyclin D1.
c) With chromosomal loss of 9q21 (encodes p16) shows a worse prognosis
d) Mostly affects younger patients (,40 years)
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4. Which of the following is not a differential diagnosis of intravascular large B-cell lymphoma?
a) Lymphangiosis carcinomatosa
b) Intralymphatic histiocytosis
c) Cryoglobulinemia
d) Intravascular CD30-positive T-cell proliferation
5. Which statement regarding EBV-associated B-cell lymphoproliferations is correct?
a) In the setting of organ transplantation, advanced age is a risk factor for the development of plasmablastic lymphoma (PBL).
b) In EBV-positive mucocutaneous ulcer the neoplastic cells express CD20 and CD30, but are negative for EBER.
c) PBL is almost exclusively found in patients with HIV infection or other immune deﬁciencies.
d) The prognosis of PBL is favourable.
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